BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11145646)

  • 1. Regulation of the CTL response by macrophage migration inhibitory factor.
    Abe R; Peng T; Sailors J; Bucala R; Metz CN
    J Immunol; 2001 Jan; 166(2):747-53. PubMed ID: 11145646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen).
    Goldberg J; Shrikant P; Mescher MF
    J Immunol; 2003 Jan; 170(1):228-35. PubMed ID: 12496404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
    Krishnan L; Sad S; Patel GB; Sprott GD
    J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
    J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody.
    Tutt AL; O'Brien L; Hussain A; Crowther GR; French RR; Glennie MJ
    J Immunol; 2002 Mar; 168(6):2720-8. PubMed ID: 11884438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
    Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K
    J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity.
    Dorothée G; Vergnon I; Menez J; Echchakir H; Grunenwald D; Kubin M; Chouaib S; Mami-Chouaib F
    J Immunol; 2002 Jul; 169(2):809-17. PubMed ID: 12097384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
    Seo N; Tokura Y; Takigawa M; Egawa K
    J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.
    Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B
    J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance.
    Li W; Lu L; Wang Z; Wang L; Fung JJ; Thomson AW; Qian S
    J Immunol; 2001 May; 166(9):5619-28. PubMed ID: 11313402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors.
    Helmich BK; Dutton RW
    J Immunol; 2001 Jun; 166(11):6500-8. PubMed ID: 11359800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.
    Salcedo R; Stauffer JK; Lincoln E; Back TC; Hixon JA; Hahn C; Shafer-Weaver K; Malyguine A; Kastelein R; Wigginton JM
    J Immunol; 2004 Dec; 173(12):7170-82. PubMed ID: 15585838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstitution of CD8+ T cells by retroviral transfer of the TCR alpha beta-chain genes isolated from a clonally expanded P815-infiltrating lymphocyte.
    Tahara H; Fujio K; Araki Y; Setoguchi K; Misaki Y; Kitamura T; Yamamoto K
    J Immunol; 2003 Aug; 171(4):2154-60. PubMed ID: 12902522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-12 administered in vivo to young and aged mice. Discrepancy between the effects on tumor growth in vivo and cytotoxic T lymphocyte generation ex vivo: dependence on IFN-gamma.
    Horvath-Arcidiacono JA; Mostowski HS; Bloom ET
    Int Immunol; 1996 May; 8(5):661-73. PubMed ID: 8671653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
    Chakraborty M; Abrams SI; Camphausen K; Liu K; Scott T; Coleman CN; Hodge JW
    J Immunol; 2003 Jun; 170(12):6338-47. PubMed ID: 12794167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC.
    Dalyot-Herman N; Bathe OF; Malek TR
    J Immunol; 2000 Dec; 165(12):6731-7. PubMed ID: 11120791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.
    Matsui S; Ahlers JD; Vortmeyer AO; Terabe M; Tsukui T; Carbone DP; Liotta LA; Berzofsky JA
    J Immunol; 1999 Jul; 163(1):184-93. PubMed ID: 10384115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Kerkvliet NI; Baecher-Steppan L; Shepherd DM; Oughton JA; Vorderstrasse BA; DeKrey GK
    J Immunol; 1996 Sep; 157(6):2310-9. PubMed ID: 8805628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.